Skip to content

Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire

Lynch Syndrome Carriers' Uterine Cancer Health Assessment: Sampling and DNA-based Detection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07194551
Acronym
Lynch-SCAN
Enrollment
30
Registered
2025-09-26
Start date
2025-08-29
Completion date
2027-04-01
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer, Lynch Syndrome

Keywords

Reproductive Health, Lynch Syndrome

Brief summary

The goal of this study is to find out if self-collected vaginal swabs can be used to detect early signs of uterine cancer or related conditions in people with Lynch syndrome (LS) who still have their uterus. The study also tests if people with LS are willing and able to collect these samples themselves and whether they find the process acceptable. The main questions this study asks are: * Will people with LS take part in self-collection of vaginal samples, and do they find it acceptable? * Can vaginal DNA mutations predict cancer risk or match results from other genetic or biopsy testing? * Can a cancer risk model used in the general population also help identify risk in people with LS? Participants will: * Answer a health questionnaire about lifestyle and symptoms * Collect their own vaginal swabs and measure their vaginal pH at home using a self-collection kit * Complete short surveys around the time of self-collection and at the end of the study

Interventions

COMBINATION_PRODUCTVaginal DNA swab, microbiome swab and pH test

Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.

Sponsors

University of British Columbia
Lead SponsorOTHER
Vancouver Coastal Health Research Institute
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with Lynch syndrome (confirmed by genetic testing). * Have an intact uterus. * Age 30 years or older.

Exclusion criteria

* History of endometrial cancer or endometrial hyperplasia. * History of pelvic radiation or endometrial ablation. * Pregnant at the time of study enrolment or during the study.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility and Acceptability of Self-collected Vaginal DNA to Assess for the Presence of Mutations Related to EC or EC PrecursorsThrough study completion, anticipated 1-2 yearsFeasibility will be measured by enrollment and adherence rates. Enrollment is defined as interested individuals completing the first round of self-collection. Adherence is defined as compliance with returning vaginal DNA samples, completing the health questionnaire, and submitting the exit survey. Acceptability will be measured through responses to a questionnaire post-self-collection and an exit survey, evaluating ease and overall experience with the self-collection process.

Countries

Canada

Contacts

CONTACTAline Talhouk, PhD
a.talhouk@ubc.ca604-875-4111
CONTACTResearch Assistant
604-875-4111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026